Hospital-acquired Infections are highly common and the incidence is not limited to the developing world. As per a World Health Organization report, of 100 patients who are hospitalized world over, 10 from developing nations contract at least one HAI; 7 from developed nations contract minimum one. In fact, in the year 2014, it was found that in the NHS hospitals, one in 16 people acquired a health care-associated infection. And, the situation is still grim. Recently, an 80 year old woman in UK died of contracting Coronavirus in a hospital in Wales.
This demonstrates a pressing need for hospital-acquired infection treatment across the world, especially in times of a raging pandemic that is highly contagious – COVID-19. As per Transparency Market Research, the global market would chart a decent growth rate over the coming few years, paving way for abundant opportunities of growth, which market players would be quick to tap into. It is worth mentioning here that so far, some of the most common infections that have marked the healthcare setting are pneumonia, urinary tract infection (UTI), blood stream infection and surgical-site infection (SSI).
Increase in Incidence of Chronic Illness and in Number of Geriatric People to Drive Growth
Patient groups most vulnerable to these infections are newborns and people over the age of 60. It is significant that from 1980, the population grew from 382 million to 962 million in 2017. And, it is positioned to grow further – will double by the year 2050. This translates to nearly 2.1billion people aged 60 and over by the year 2050. Not only does the geriatric age group require surgical procedures often but a weaker immunity brings them to the hospital setting very often, making them highly susceptible to HAIs. However, it is equally important to make note of the fact that hospital staff and caregivers are also vulnerable to such infections.
Research shows that intensive care units for infants are the most sterilized sections as they are prone to experiencing severe infections. This is an area that is set to create a slew of opportunities for market players over the coming few years.In India alone, 23die out of every 1000 live birthsas per United Nations Children’s Fund.
Additionally, it is worth noting that chronic illnesses are also witnessing an increase in incidence world over due to poor diets and a sedentary lifestyle. In the United states alone, the number of people with one chronic illnesses is high – six in every ten people. Besides, four in every 10 people suffer from more than one.
Developing Nations to Present Players Operating the Global Hospital-Acquired Infection Treatment Market with a Multitude of Untapped Opportunities
A number of countries, particularly the developing ones, do not have proper surveillance systems to detect and manage HAIs. This generates untapped opportunities for global hospital-acquired infection treatment market players.However, with endemics and now a pandemic marking the landscape, many players will witness growth, driving the market on an upward growth trajectory.
North American and European regions will lay claim to a prominent share of the global hospital-acquired infection treatment market owing to high awareness, presence of strong players, and a rapidly ageing population.
Vendor Landscape – Fragmented and Competitive
The vendor landscape of the global hospital-acquired infection treatment market is fragmented owing to a large number of regional and international players. Some of the prominent ones in the market include Eli Lilly, Bristol-Mers Squibb Company, Daiichi Sankyo Inc. AstellasPharma Inc., Aridis Pharmaceuticals Inc., GlaxoSmithKline plc,Cipla Inc., Merck and Co. Inc., Johnson and Johnson Services Inc., Bayer AG, Pfizer Inc., Abbott Laboratories, and others.
To know more about this research report,please visit our Report: https://www.transparencymarketresearch.com/hospital-acquired-infection-treatment-market.html